Collaborative Framework Agreement


 

TIDMPYN 
 
 
Phynova Group PLC 
28 July 2009 
 
28 July 2009 
 
 
Phynova Group PLC 
("Phynova" or the "Company") 
 
 
Phynova Announces Collaboration with Chrysalis Health & Beauty Solutions 
Limited ("Chrysalis") to Promote and Commercialise Candidate Functional 
Ingredient and Over the Counter ("OTC") Products in Europe 
 
 
Phynova (AIM: PYN), the developer of prescription pharmaceuticals, functional 
ingredients for the cosmetic, food and supplement industries and OTC products 
capable of being registered under the Traditional Herbal Medicinal Products 
scheme, today announces that it has signed a Collaborative Framework Agreement 
with Chrysalis. Chrysalis is a specialist company based in Nottingham providing 
consultation services and products to the Health and Beauty sectors. 
 
 
Under the agreement Phynova will use Chrysalis' services over the next two years 
for the promotion and commercialisation of Phynova's functional ingredient and 
OTC product candidates in Europe. Phynova's product candidates include 'BCL-6', 
a skin anti-ageing ingredient, and other functional food ingredients with 
potential in the treatment of Type II diabetes and in combating fatigue and 
improving sleep quality in middle aged and older people. Phynova is 
collaborating in the development of these products with its joint venture 
partner in China, Botanic Century Beijing Ltd ("BCCL") and has a collaboration 
with Tasly Modern Chinese Medicine Resource Ltd, a subsidiary of the Tasly Group 
of Tianjin, China, one of the world's largest producers of botanical drugs. 
Phynova is also developing products suitable for registration under the EU's 
Traditional Herbal Medicinal Products (THMP) scheme and is already in discussion 
with a number of companies seeking to create new brands or to maintain OTC 
herbal products on the market in compliance with the EU Directive's 2011 
deadline for registration. 
 
 
Phynova's CEO Robert Miller commented "As we have reported previously Phynova is 
developing several pipeline opportunities capable of generating near term 
revenues in the functional ingredient and OTC markets. With this agreement we 
believe we have added greatly to our chances of achieving commercial success. 
The team at Chrysalis supplies us strong complementary capabilities, with 
support in areas such as formulation and pricing, proof of efficacy testing, 
ingredient and product promotion and brand development. We believe Chrysalis 
will help shorten the time to achieving commercial success on the path that 
begins with our own discoveries and those of our collaborators in China." 
 
 
For further information, please contact: 
 
 
+-------------------------------------+-------------------------------------+ 
| Phynova Group PLC                   |                                     | 
+-------------------------------------+-------------------------------------+ 
| Robert Miller (CEO)                 |                 +44 (0) 1993 880700 | 
+-------------------------------------+-------------------------------------+ 
| Tony Mills (CCO)                    |                                     | 
+-------------------------------------+-------------------------------------+ 
|                                     |                                     | 
+-------------------------------------+-------------------------------------+ 
| Nominated Adviser and Broker:       |                                     | 
+-------------------------------------+-------------------------------------+ 
| John East & Partners Limited, a subsidiary of Merchant Securities PLC     | 
+---------------------------------------------------------------------------+ 
| John East/Simon Clements            |                +44 (0) 20 7628 2200 | 
+-------------------------------------+-------------------------------------+ 
 
 
 
 
Notes to Editors: 
 
 
About Phynova 
 
 
Phynova is a UK company developing new prescription pharmaceuticals derived from 
plants used in Chinese medicines, functional ingredients for the cosmetic, food 
and supplement industries and OTC products capable of being registered under the 
Traditional Herbal Medicinal Products scheme. 
 
 
For further information please visit www.phynova.com. 
 
 
 
 
About Chrysalis Health & Beauty 
 
 
Chrysalis Health & Beauty is a UK company specialising in the commercialisation 
of new products and concepts for use in the Health & Beauty markets. With 
extensive in-house technical and marketing experience, Chrysalis works with 
academic, research-orientated and marketing-based organisations offering clear 
routes to market and numerous services. Clients vary from businesses requiring 
advice and assistance in taking a new product to market, to companies wishing to 
outsource the entire commercial aspects of particular projects. With a worldwide 
network of partners, Chrysalis can help to launch products on a global scale 
rapidly and effectively. Chrysalis' typical clients include Brands, R&D 
companies, Retailers and Manufacturers of raw materials or finished goods. 
 
 
For further information please visit www.chrysalisweb.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRARPMPTMMTTMIL
Phynova (LSE:PYN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024